Enesi Pharma Selected to Showcase Unique ImplaVax® Needle-Free Solid Dose Vaccine Platform in Inaugural ‘Lightning Talk’ Session at BARDA Industry Day

Oxford, UK – 16 October 2018. Enesi Pharma, an innovative pharmaceutical company developing unique injectable solid dose vaccine products, is honoured to have been selected to present a ‘Lightning Talk’ at The Biomedical Advanced Research and Development Authority (BARDA) Industry Day on 29-30 October at the Grand Hyatt in Washington DC, U.S.  

BARDA is a key component of the U.S. Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR). BARDA Industry Day 2018 will feature two days of exciting speakers, breakout sessions and networking opportunities. This year’s theme focuses on the importance of innovation and collaboration for advancing research and development of medical countermeasures against serious health security threats.

Enesi VP Product Development, Dr Ludovic Bonnet, will showcase the Company’s innovative ImplaVax® needle-free solid dose vaccine platform as one of only eight selected ‘Lightning Talks’ in a session entitled ‘Novel ImplaVax Solid Dose Vaccine Technology: Making a Material Impact on DRIVe Strategy’ at 1:00pm ET on 29 October. DRIVe (Division of Research, Innovation and Ventures) was established in June 2018 by BARDA to spur research and innovation and help build a more robust pipeline of transformative health security products and technologies to protect Americans from 21st century health security threats.

During his talk, Dr Bonnet will highlight the innate performance benefits of ImplaVax enabled vaccines.  Such benefits demonstrate the potential of ImplaVax to enhance vaccination programmes for military and other at-risk personnel as well as optimising the national strategic stockpile and providing a rapidly deployable option for individuals and populations who have been exposed to emergent threat pathogens and infectious diseases.

The Company has recently announced collaborations to evaluate opportunities for ImplaVax-enabled vaccines with the Walter Reed Army Institute of Research (Shigella infection) and Public Health England (emergent threat Pathogens, including Anthrax recombinant Protective Antigen (rPA) and Crimean-Congo Haemorrhagic Fever).

David Hipkiss, Enesi CEO commented

‘We are delighted and honoured to be selected as one of only eight companies to present a Lightning Talk at this inaugural event. We are convinced, from our experience developing ImplaVax and from our discussions with vaccine developers around the world, that our technology has the potential to address some of their biggest concerns and priorities. As evidenced by our recent collaborations with Walter Reed and Public Health England, we are focused on becoming a key strategic partner to such institutions to make a material difference to public health globally.”